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Summary
Background Invasive pneumococcal disease remains an important health priority owing to increasing disease incidence 
caused by pneumococci expressing non-vaccine serotypes. We previously defined 621 Global Pneumococcal Sequence 
Clusters (GPSCs) by analysing 20 027 pneumococcal isolates collected worldwide and from previously published genomic 
data. In this study, we aimed to investigate the pneumococcal lineages behind the predominant serotypes, the mechanism 
of serotype replacement in disease, as well as the major pneumococcal lineages contributing to invasive pneumococcal 
disease in the post-vaccine era and their antibiotic resistant traits.
Methods We whole-genome sequenced 3233 invasive pneumococcal disease isolates from laboratory-based 
surveillance programmes in Hong Kong (n=78), Israel (n=701), Malawi (n=226), South Africa (n=1351), The Gambia 
(n=203), and the USA (n=674). The genomes represented pneumococci from before and after pneumococcal 
conjugate vaccine (PCV) introductions and were from children younger than 3 years. We identified predominant 
serotypes by prevalence and their major contributing lineages in each country, and assessed any serotype replacement 
by comparing the incidence rate between the pre-PCV and PCV periods for Israel, South Africa, and the USA. We 
defined the status of a lineage as vaccine-type GPSC (≥50% 13-valent PCV [PCV13] serotypes) or non-vaccine-type 
GPSC (>50% non-PCV13 serotypes) on the basis of its initial serotype composition detected in the earliest vaccine 
period to measure their individual contribution toward serotype replacement in each country. Major pneumococcal 
lineages in the PCV period were identified by pooled incidence rate using a random effects model.
Findings The five most prevalent serotypes in the PCV13 period varied between countries, with only serotypes 5, 12F, 
15B/C, 19A, 33F, and 35B/D common to two or more countries. The five most prevalent serotypes in the PCV13 
period varied between countries, with only serotypes 5, 12F, 15B/C, 19A, 33F, and 35B/D common to two or more 
countries. These serotypes were associated with more than one lineage, except for serotype 5 (GPSC8). Serotype 
replacement was mainly mediated by expansion of non-vaccine serotypes within vaccine-type GPSCs and, to a lesser 
extent, by increases in non-vaccine-type GPSCs. A globally spreading lineage, GPSC3, expressing invasive serotypes 8 
in South Africa and 33F in the USA and Israel, was the most common lineage causing non-vaccine serotype invasive 
pneumococcal disease in the PCV13 period. We observed that same prevalent non-vaccine serotypes could be 
associated with distinctive lineages in different countries, which exhibited dissimilar antibiotic resistance profiles. In 
non-vaccine serotype isolates, we detected significant increases in the prevalence of resistance to penicillin (52 [21%] 
of 249 vs 169 [29%] of 575, p=0·0016) and erythromycin (three [1%] of 249 vs 65 [11%] of 575, p=0·0031) in the PCV13 
period compared with the pre-PCV period.
Interpretation Globally spreading lineages expressing invasive serotypes have an important role in serotype 
replacement, and emerging non-vaccine serotypes associated with different pneumococcal lineages in different 
countries might be explained by local antibiotic-selective pressures. Continued genomic surveillance of the dynamics 
of the pneumococcal population with increased geographical representation in the post-vaccine period will generate 
further knowledge for optimising future vaccine design.
Funding Bill & Melinda Gates Foundation, Wellcome Sanger Institute, and the US Centers for Disease Control.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Pneumococcal conjugate vaccines (PCVs), thus far 
targeting up to 13 pneumococcal serotypes that account 
for most of the disease in infants, have substantially 
reduced the global burden of invasive pneumococcal 
disease in children.1–5 Despite the success of PCVs, 
Articles
2 www.thelancet.com/infection   Published online June 10, 2019   http://dx.doi.org/10.1016/S1473-3099(19)30297-X
invasive pneumococcal disease remains an important 
health priority owing to an increase in the incidence of 
disease caused by non-vaccine serotypes, an event known 
as serotype replacement. Serotype replacement has been 
reported for several countries, but not the USA, after 
the intro duction of the 13-valent PCV (PCV13), and 
the magnitude of increases in non-vaccine serotypes 
varies by country.1–3,6–8 Although studies3,9–12 characterising 
serotype replacement in cases of invasive pneumococcal 
disease have primarily focused on changes in serotypes, 
mechanisms by which the pneumococcal population 
evolves and adapts to the selective pressure of PCVs, and 
the relative contribution of each mechanism to the 
increase in non-vaccine serotypes, are not completely 
understood.
Two mechanisms of serotype replacement have been 
suggested. The first is expansion of non-vaccine-type 
lineages to partly fill the niche vacated by vaccine-type 
lineages.13 The second is within-lineage expansion of 
non-vaccine serotypes, which can be explained as a 
concomitant increase in non-vaccine serotypes and 
decrease in vaccine serotypes within a lineage after PCV 
introduction, usually through expansion of existing non-
vaccine-type components rather than contemporaneous 
capsular switching.14,15 Multiple serotypes (vaccine and 
non-vaccine) expressed by a single pneumococcal lineage 
were not unusual14,16 because pneumococci is able to 
replace capsular biosynthesis genes through acquisition 
of foreign DNA by natural genetic transformation.17
The Global Pneumococcal Sequencing (GPS) project 
was set up to guide the design of preventive measures for 
pneumococcal diseases beyond PCV13 by defining 
pneumococcal lineages across a global pneumococcal 
population and attempting to capture how lineages evade 
vaccines. As part of the GPS project, a high-resolution 
population structure of 621 Global Pneumococcal 
Sequence Clusters (GPSCs) was defined by analysing 
20 027 pneumococci genomes.18 In this study, we aimed to 
identify the predominant serotypes causing invasive 
pneumococcal disease among children younger than 
3 years and their associated lineages after the introduction 
of PCV13 in six countries, investigate the mechanisms of 
serotype replacement in disease, and identify international 
lineages contributing to post-PCV13 invasive pneu- 
mococcal disease and report their antibiotic-resistant 
traits.
Methods
Study design
From the GPS database (last accessed June 1, 2017), we 
extracted genomic data from invasive isolates causing 
disease in children younger than 3 years in six countries 
(Hong Kong, Israel, Malawi, South Africa, The Gambia, 
and the USA). For each country, the collection 
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Research in context
Evidence before this study
We searched PubMed, using the terms “pneumococcal 
conjugate vaccine” AND “genome” OR “genotype” OR “clone”, 
for papers published in English between Jan 1, 2000, 
and Aug 21, 2018. We searched for population-based studies of 
invasive pneumococcal disease that reported changes in 
serotype and genotype (or clone) before and after 
pneumococcal conjugate vaccine (PCV) introduction. 
After reviewing 288 articles, 21 met inclusion criteria. 
The effects of 7-valent PCV (PCV7) were measured in 11 studies, 
10-valent PCV (PCV10) in three, and 13-valent PCV (PCV13) in 
seven. These studies were done at the national or regional level, 
and the majority delineated genotypes using multilocus 
sequence typing or pulsed-field gel electrophoresis. Only one 
study from the USA, which reported the post-PCV7 changes 
using 349 isolates, delineated pneumococcal genotypes using 
whole-genome sequences. No published reports were available 
investigating the changes in both serotype and clone before 
and after PCV10 or PCV13 introduction from an international 
perspective. Our accompanying paper reported an international 
definition of pneumococcal lineages or Global Pneumococcal 
Sequence Clusters (GPSCs) using 20 027 pneumococcal 
genomes. This is the first study to make full use of 
whole-genome sequences to delineate pneumococcal lineages 
with a standardised clustering nomenclature. The GPSC 
reference database can be updated over time to accommodate 
novel GPSCs identified in the future. This genomic typing 
scheme is key to contextualise disease, antibiotic resistance, 
and vaccine effect at a local and international level.
Added value of this study
We used the international definition of Global Pneumococcal 
Sequence Clusters to assess the effects of PCVs on the 
population structure of invasive pneumococcal disease across 
several countries. This standardised and high-resolution typing 
scheme allows for the identification of key international 
lineages driving serotype replacement in disease and changes in 
the prevalence of antibiotic resistance in the post-PCV13 era.
Implications of all the available evidence
Use of whole-genome sequencing and epidemiological data in 
pneumococci surveillance programmes provides enhanced 
understanding of the changes in pneumococcal serotypes, 
genotypes, and antimicrobial resistance nationally and 
internationally after the introduction of PCV13. Provision of a 
user-friendly web tool that enables analysis of new genomic 
data with rapid GPSC assignment, serotyping, and antimicorbial 
resistance prediction is key for ongoing genomic surveillance. 
We await confirmation of the pneumococcal lineages we found 
to be associated with serotype replacement from surveillance 
programmes that extend beyond 4 years post-PCV13 with 
greater geographical representation. The knowledge generated 
should drive effective next-generation vaccine design.
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represented pneumococci from before and after the 
introduction of 7-valent PCV (PCV7) and PCV13 into the 
universal immunisation programmes.
An invasive pneumococcal disease case was defined as 
pneumococci cultured from a normally sterile site. The 
overall GPS database comprises 13 454 genomes, 
including 8605 disease and 4849 carriage isolates, 
representing 30 countries from Africa (n=7928), Asia 
(n=2381), North America (n=1684), South America 
(n=1027), and Europe (n=434). Collections from countries 
other than the six included in this study either did not 
have 50 or more isolates from before and after the 
introduction of PCVs, or were biased by sampling a 
particular serotype, and were thus not included in this 
analysis (appendix 1). Pneumococcal isolates collected 
from children younger than 3 years were selected 
because this age group represents the primary target for 
vaccination; any serotype and clonal changes in response 
to vaccine-induced selective pressure are expected to be 
most quickly reflected in this population. The vaccination 
schedule, catch-up scheme, and PCV uptake for each of 
the six countries are summarised in table 1.
Data processing
The pnuemococcal isolates in the GPS database 
were whole-genome sequenced on an Illumina HiSeq 
Sequencer. We included the pneumococcal genomes 
from the GPS database on the basis of the aforementioned 
criteria and analysed them as previously described.18 In 
brief, pneumococcal isolates were clustered into GPSCs 
on the basis of their shared sequence and gene content 
using a fast and flexible bacterial genomic software, 
Population Partitioning Using Nucleotide K-mers 
(PopPUNK).21 Serotypes were typed in silico,22,23 and 
antibiotic susceptibility for penicillin (encoded by the 
genes pbp1A, pbp2B, and pbp2A), chloramphenicol (cat), 
erythromycin (ermB, ermTR1, and mefA), cotrimoxazole 
(folA and folP), and tetracycline (tet[M], tet[O], and 
tet[S/M]) was predicted using the sequencing reads and 
the published tools developed by the USA Centers 
for Disease Control.24–26 The genome sequences were 
deposited in the European Nucleotide Archive.
We compiled metadata, including age, year of 
collection, and sample source, from the GPS database. 
On the basis of the year of PCV introduction, we grouped 
isolates into three vaccine periods: those from the pre-
PCV period (years when no conjugate vaccine was used 
and the year of first PCV introduction), those from the 
PCV7 period (from the second year of PCV7 introduction 
to the first year of PCV13 introduction), and those from 
the PCV13 period (from the second year of PCV13 
introduction to the end of the collection year). Serotypes 
were grouped into two categories: vaccine serotypes (1, 3, 
4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) and non-
vaccine serotypes (serotypes not included in PCV13 and 
non-typeable). We defined the status of a lineage as 
vaccine serotype GPSC (≥50% PCV13 serotypes) or 
non-vaccine serotype GPSC (>50% non-PCV13 serotypes) 
on the basis of its initial serotype composition detected 
in the earliest vaccine period. The GPSC assignments, 
in-silico serotype, genotypic antimicrobial resistance, 
European Nucleotide Archive accession numbers, and 
metadata are collated in appendix 2.
Statistical analysis
Data on the annual incidence of invasive pneumococcal 
disease before and after the introduction of PCV7 or 
PCV13 was available for South Africa, Israel, and the 
USA. For each of these three countries, we used the 
Poisson regression to calculate the incidence rate ratios 
(IRRs) of total invasive pneumo coccal disease, non-
vaccine-type invasive pneumococcal disease, or individual 
GPSC using the estimated incidence rate of invasive 
pneumococcal disease per year for each of the two 
vaccine periods.27 If overdispersion was detected, we 
reported the robust standard error for minor violation of 
the Poisson regression assumption measured by 
goodness-of-fit (p value ranged between 0·01 and 0·05) 
or used the negative bionomial regression (Poisson 
goodness-of-fit p value <0·01). If neither model fit, we 
calculated IRRs using the average annual incidence for 
the two periods. To avoid IRRs being calculated as zero or 
infinity, we added a constant number of one to all the 
estimated invasive pneumococcal disease cases for both 
periods if a GPSC was not observed in one of the two 
PCV periods. Serotype replacement was detected if the 
IRR and lower bound for 95% CI were above one.28 By 
use of the random effects model in the R meta package,29 
a pooled incidence rate of non-vaccine-type invasive 
pneumococcal disease for each GPSC was calculated for 
Israel, South Africa, and USA.
For Hong Kong, Malawi, and The Gambia, increase of 
a particular non-vaccine serotype in the overall population 
or within a GPSC was calculated as a proportion of all 
non-vaccine serotypes and compared between vaccine 
periods using Fisher’s exact test. For these countries, 
incidence rates could not be calculated owing to 
unavailable information about the actual number of 
invasive pneumococcal disease cases per year and 
estimates of the child population in the study period.
A generalised linear binomial regression was used to 
detect changes in antimicrobial non-susceptibility to 
penicillin, chloramphenicol, erythromycin, cotrimoxazole, 
and tetracycline between the pre-PCV and PCV13 periods, 
where country was included as a dependent variable to 
account for variations in resistance prevalence between 
countries. Odds ratios indicating the invasive disease 
potential of serotypes were calculated previously,18 whereby 
a country-matched and year-matched collection of disease 
(n=1081) and carriage (n=1434) isolates from children 
younger than 7 years was used to calculate a pooled odds 
ratio with a meta-analysis approach.18,30,31 The invasive 
disease potential of serotypes measured in the child 
population younger than 7 years was shown to be 
See Online for appendix 1
See Online for appendix 2
For the European Nucleotide 
Archive see https://www.ebi.ac.
uk/ena
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conserved in the child population younger than 3 years.32 
Two-sided p values of less than 0·05 were considered 
significant. Multiple testing correction was done using the 
Benjamini-Hochberg false discovery rate of 5% when 
number of tests is greater than ten. Statistical tests were 
done in R version 3.5.2. R scripts used for analyses are 
available in a public depository. Further details of the 
methods are included in appendix 1.
Role of the funding source
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Of the 8605 disease isolates in the GPS database, 
4416 were from children younger than 3 years from 
27 countries (appendix 1). Of these, we included whole-
genome sequencing data from 3233 isolates collected 
from Hong Kong (n=78), Israel (n=701), Malawi (n=226), 
South Africa (n=1351), The Gambia (n=203), and the 
USA (n=674; table 1). For the PCV13 period, sequences 
were available for 1 year in the USA, 2 years in Malawi, 
South Africa, and The Gambia, and 4 years in Israel and 
Hong Kong (table 1).
Before the introduction of PCV, all PCV7 serotypes (1, 5, 
6B, 14, 18C, 19F, and 23F) and one PCV13 serotype (6A) 
were prevalent serotypes in two or more countries. Apart 
from Malawi, we observed changes in major serotypes in 
the PCV7 period, in which PCV7 serotypes (14, 19F, 23F), 
PCV13 unique serotypes (1, 3, 5, 19A), and non-vaccine 
serotypes (15B/C and 12F) were among the five most 
common to at least two countries (figure 1). Following the 
introduction of PCV13, invasive pneumococcal disease 
caused by vaccine-type pneumococci significantly 
decreased in incidence in Israel, South Africa, and the 
USA and in prevalence for Hong Kong, Malawi, and The 
Gambia (appendix 1). Non-vaccine-type pneumococci 
accounted for the majority of invasive pneumococcal 
disease cases in all countries in the PCV13 period, except 
for Hong Kong where PCV13 serotypes 3 and 19A still 
accounted for 13 (65%) of 20 cases (figures 1 and 2; 
appendix 1). The five most prevalent serotypes (vaccine-
type and non-vaccine type) in the PCV13 period varied 
between countries, but serotypes 5, 12F, 15B/C, 19A, 33F, 
and 35B/D were common to two or more countries 
(figure 2; appendix 1).
The major lineages associated with these shared 
serotypes also differed between countries, except for 
lineages GPSC3, GPSC5, GPSC8, and GPSC26 (figure 2). 
In the PCV13 period, GPSC3 was present in three of 
six countries, accounting for all invasive pneumococcal 
disease cases caused by serotype 8 pneumococci (the 
most common serotype) in South Africa and all disease 
cases caused by serotype 33F (the fourth most common) 
in the USA and Israel (the fifth most common). GPSC5 
was also found in three of six countries, predominantly 
expressing 35B/D in South Africa and Malawi but 
serotype 19A in Israel. It contributed to 19 (83%) of the 
23 serotype 35B/D invasive pneumococcal disease 
isolates in South Africa (ranked second) in the PCV13 
period, all four 35B/D isolates in Malawi (ranked first), 
and nine (53%) of 17 serotype 19A isolates (ranked fourth) 
in Israel. GPSC8, which exclusively expressed serotype 5, 
represented all serotype 5 isolates in The Gambia (n=5) 
and Israel (n=26) in the PCV13 period. GPSC26 was 
China Israel Malawi South Africa The Gambia USA
Regions Hong Kong Nationwide Blantyre Nationwide Nationwide 10 of 50 states*
World Bank income group High income High income Low income Upper-middle income Low income High income
Year of PCV7 introduction 
(vaccine schedule†)
2009 
(3 + 1, with catch-up)
2009 
(2 + 1, with catch-up)
No PCV7 introduction 2009 
(2 + 1, without catch-up)
2009 
(3 + 0, without catch-up)
2000 
(3 + 1, with catch-up)
Year of PCV10 or PCV13 
introduction (vaccine schedule)
PCV10 in 2010 
(3 + 1, with catch-up); 
PCV13 in 2011 
(3 + 1, with catch-up)
PCV13 in 2010 
(2 + 1, without 
catch-up)
PCV13 in 2011 
(3 + 0, without 
catch-up)
PCV13 in 2011 
(2 + 1, with limited 
catch-up for children 
<30 months old)
PCV13 in 2011 
(3 + 0, without 
catch-up)
PCV13 in 2010 
(3 + 1, with catch-up)
PCV13 uptake during the study 
period‡
95% 92–94% 87–88% 69–72% 96–97% 92%
Number of isolates (collection period)
Pre-PCV 45 (1995–2001) 357 (2005–09) 213 (1997–2011) 763 (2005–09) 62 (1996–2009) 137 (1998–99)
PCV7 13 (2010–11) 67 (2010) None 297 (2010–11) 55 (2010–11) 410 (2001–09)
PCV13 20 (2012–15) 277 (2011–14) 13 (2014–15) 291 (2013–14) 86 (2013–14) 127 (2012)
Total 78 701 226 1351 203 674
PCV=pneumococcal conjugate vaccine. PCV7=7-valent PCV. PCV10=10-valent PCV. PCV13=13-valent PCV. *California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon, and 
Tennessee.19 †The 3 + 1 immunisation schedule consisted of a standard three-dose primary series at 2, 4, and 6 months of age and a booster dose at 12–15 months; the 2 + 1 schedule consisted of two-dose 
primary series at 2 and 4 months of age and a booster dose at 12 months in Israel and at 6 and 14 weeks of age and a booster dose at 9 months of age in South Africa; the 3 + 0 immunisation schedule consisted 
of three-dose primary series at 6, 10, and 14 weeks of age in Malawi and at 2, 3, and 4 months of age in The Gambia. Catch-up immunistaion was given to children whose vaccination had been delayed. ‡PCV13 
uptake in the study period was based on WHO statistics.20
Table 1: Characteristics of country-specific datasets containing pneumococcus invasive isolates from children younger than 3 years
For R scripts see https://github.
com/rgladstone/GPSCs/tree/
master/lo_et_al
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Figure 1: Serotype distribution among invasive pneumococcal isolates from children younger than 3 years before and after the introduction of PCV13
Vaccine serotypes are represented by solid fill and non-vaccine-serotypes by coloured hatched patterns. The five most prevalent serotypes for each period are labelled. 
Serotypes with fewer than two isolates are not labelled. PCV=pneumococcal conjugate vaccine. PCV7=7-valent PCV. PCV13=13-valent PCV. 
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mainly composed of serotype 12F (34 [97%] of 35) and 
accounted for all serotype 12F isolates (n=20, ranked 
first) in The Gambia and ten (45%) of 22 serotype 12F 
isolates (ranked second) in South Africa in the PCV13 
period. A few isolates from GPSC26 were also observed 
in Malawi (n=1) and Israel (n=3) in the PCV13 period.
Serotype replacement was detected in Israel (IRR 2·1, 
95% CI 1·6–2·9, p<0·0001), but not in South Africa 
(1·2, 0·8–1·7, p=0·35) or the USA (1·1, 0·5–2·4, p=0·84). 
The increases in non-vaccine-type invasive pneumococcal 
disease did not offset the overall invasive pneumococcal 
disease reductions in these three countries (IRR 0·42, 
95% CI 0·34–0·43 for Israel; 0·27, 0·23–0·30 for 
South Africa; 0·08, 0·07–0·10 for the USA; p<0·0001 
for all comparisons; appendix 1). We observed significant 
increases in incidence of non-vaccine-type GPSCs in 
Israel and increases in incidence of non-vaccine-type 
components within vaccine-type GPSCs in Israel and 
South Africa (table 2).
Pooling GPSCs by their classification as either non-
vaccine type or vaccine type, we observed that more 
non-vaccine-type GPSCs than vaccine-type GPSCs 
contributed to cases of non-vaccine-type invasive 
pneumococcal disease in Israel, South Africa, and the 
USA in the PCV13 period, although the magnitude of 
increase in disease caused by non-vaccine serotypes 
(measured by IRR) was larger for vaccine-type than for 
non-vaccine-type GPSCs (table 2). The contribution of 
either mechanism varied between countries (table 2; 
appendix 1).
In the PCV13 period, eight non-vaccine-type GPSCs 
increased in incidence (GPSC3, 59, 55, 168, 25, 139, and 
132, descending order of pooled incidence rate) or in 
prevalence (GPSC5). Significant increases in incidence 
of non-vaccine serotypes occurred within three vaccine-
type GPSCs (GPSC11, 5, and 6; table 3). Among them, 
the GSPC5 lineage was observed to be significantly 
expanding in more than one country in the PCV13 period; 
the expansions of other GPSCs were country-specific 
(table 3). We also observed that lineages expressing 
the same serotypes could change differently after the 
introduction of PCV13 within a country. For example, of 
the two lineages in Israel expressing serotype 12F in the 
PCV13 period (GPSC26 and GPSC55), only GPSC55 
significantly increased in that period (appendix 1).
Pooled incidence rates of the ten most prevalent 
international lineages causing non-vaccine-type invasive 
pneumococcal disease in the PCV13 period are listed in 
table 3. GPSC3, which mainly expressed two invasive 
serotypes (8 and 33F),18 was the predominant lineage 
causing non-vaccine-type invasive pneumococcal disease 
in the PCV13 period. GPSC26 (ranked sixth) was another 
lineage expressing invasive serotypes: of the 63 isolates 
from all vaccine periods, 57 (90%) were serotype 12F and 
six (10%) were serotype 46. In The Gambia, GPSC26 
accounted for all serotype 12F isolates and became the 
leading cause of invasive pneumococcal disease in the 
PCV13 period. The other eight lineages either expressed 
non-vaccine serotypes that were significantly associated 
with carriage (GPSC11, 48, and 9) or non-vaccine 
Israel South Africa USA
Mechanism 1*
Number of non-VT GPSCs 36 66 24
Non-VT IPD cases caused by non-VT GPSCs in the 
pre-PCV period
49/56 (88%) 111/122 (91%) 7/11 (64%)
Non-VT IPD cases caused by non-VT GPSCs in the 
PCV13 period†
153/195 (78%) 168/209 (80%) 63/106 (59%)
Incidence of non-VT IPD caused by non-VT GPSCs 
in the pre-PCV period, per 100 000 children
8·2 4·5 6·8
Incidence of non-VT IPD caused by non-VT GPSCs 
in the PCV13 period, per 100 000 children
15·8 4·7 6·0
IRR (95% CI, p value)‡ 1·9 (1·4–2·6, 
p<0·0001)
1·1 (0·7–1·6, 
p=0·78)
0·9 (0·7–1·2, 
p=0·40)
Mechanism 2§
Number of VT GPSCs 47 53 29
Non-VT IPD cases caused by VT GPSCs in the 
pre-PCV period
7/56 (12%) 11/122 (9%) 4/11 (36%)
Non-VT IPD cases caused by VT GPSCs in the 
PCV13 period†
42/195 (22%) 41/209 (20%) 43/106 (41%)
Incidence of non-VT IPD caused by VT GPSCs in 
the pre-PCV period, per 100 000 children
1·3 0·4 2·6
Incidence of non-VT IPD caused by VT GPSCs in 
the PCV13 period, per 100 000 children
4·2 1·1 4·1
IRR (95% CI, p value)‡ 3·4 (1·8–6·3; 
p<0·0001)
2·5 (1·6–3·9; 
p<0·0001)
1·6 (1·0–2·4; 
p=0·12)
VT=vaccine type. GPSC=Global Pneumococcal Sequence Cluster. IPD=invasive pneumococcal disease. 
PCV=pneumococcal conjugate vaccine. IRR=incidence rate ratio. *Increase in disease caused by non-VT GPSCs 
(ie, those expressing >50% non-vaccine serotypes in the pre-PCV13 period). †The PCV13 period represented 4 years 
(2011–14) in Israel, 2 years (2013–14) in South Africa, and 1 year (2012) in the USA. ‡IRRs were calculated with the 
estimated incidence of non-VT IPD caused by VT or non-VT GPSCs per year for the pre-PCV and PCV13 periods. 
§Increase in non-VT component within VT GPSCs (ie, those expressing ≥50% vaccine serotype in the pre-PCV period).
Table 2: Individual contribution of the two mechanisms toward serotype replacement in IPD
Hong Kong
2012–15 (n=20)
Israel
2011–14 (n=277)
USA
2012 (n=127)
South Africa
2013–14  (n=291)
The Gambia
2013–14 (n=86)
Malawi
2014–15 (n=13)
0 10 20 30 40 50 60 70 80 90 100
%
343 19A1
19A558
19A4
35B/D5
12 23F193
15B/C25
Other 4 serotypes
Other 31 serotypes
Other 20 serotypes
Other 40 serotypes
Other 20 serotypes
Other 9 serotypes
58
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16F33
35B/D5
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12F26/56
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33F3
22F19
12F55 15B/C11
15B/C152
83
Figure 2: Comparison of the five most prevalent pneumococcal serotypes in Global Pneumococcal Sequencing 
key sites in the PCV13 period
The five most prevalent serotypes are indicated in boxes in proportion to their prevalence. The predominant Global 
Pneumococcal Sequence Clusters (GPSCs) associated with these serotypes are written in superscript, and identical 
GPSCs are written in same colour. Blue bands indicate the serotypes shared between countries. Serotypes with 
fewer than two isolates are not listed. PCV13=13-valent pneumococcal conjugate vaccine.
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serotypes that were not significantly associated with 
disease or carriage (table 3).18
The introduction of PCV13 was associated with overall 
reductions in the prevalence of resistance to all classes 
of antibiotics, except to chloramphenicol, which was 
maintained at around 5% throughout the vaccine 
periods (table 4). Among the non-vaccine-type isolates, 
we detected significant increases in penicillin and 
erythromycin resistance and a significant decrease in 
cotrimoxazole resistance between the pre-PCV and PCV13 
periods (table 4). Of the ten most common GPSCs, 
three (GPSC5, 48, and 9) had a prevalence of penicillin 
resistance ≥90% and four (GPSC5, 26, 48, and 9) had 
64–100% of isolates non-susceptible to at least two classes 
of antibiotics (table 3). Isolates belonging to three non-
vaccine-type GPSCs (GPSC55, 59, 168, and 132) that 
significantly increased in incidence between the pre-PCV 
and PCV13 periods were 100% resistant to penicillin. 
GPSC59 also showed mefA-mediated erythromycin 
resistance, GPSC132 was additionally resistant to mefA-
mediated erythromycin and tetracycline resistance, and 
GPSC168 was additionally resistant to cotrimoxazole 
(appendix 1). Of note, GPSC26 exhibited non-susceptibility 
Pooled incidence rate 
of non-VT IPD 
(95% CI)*
Number of 
non-VT 
isolates†
Mechanism 1‡ Mechanism 2§ Penicillin 
resistance, n (%)
Not susceptible 
to two or more 
classes of 
antibiotics, n (%)
Ten most prevalent GPSCs causing non-VT IPD in the PCV13 era
GPSC3 2·70 (1·34–5·42) 71 8 (South Africa)¶ ·· 4 (6%) 15 (21%)
GPSC19 0·89 (0·28–2·82) 21 ·· ·· 0 0
GPSC11 0·86 (0·06–12·61) 32 ·· 19A→15B/C (Israel) 1 (3%) 1 (3%)
GPSC5 0·66 (0·27–1·62) 28 35B/D (Malawi) 23F→35B/D (South Africa)¶ 26 (93%) 24 (86%)
GPSC38 0·65 (0·11–3·94) 17 ·· ·· 0 0
GPSC26 0·58 (0·21–1·58) 35 ·· ·· 0 35 (100%)
GPSC36 0·49 (0·20–1·22) 12 ·· ·· 0 0
GPSC48 0·48 (0·12–1·97) 11 ·· ·· 11 (100%) 7 (64%)
GPSC9 0·47 (0·05–4·00) 13 ·· ·· 13 (100%) 13 (100%)
GPSC7 0·42 (0·07–2·64) 10 ·· ·· 0 0
Other important GPSCs in the PCV13 era
GPSC59 0·32 (0·06–1·75) 13 35B/D (USA) ·· 13 (100%) 10 (77%)
GPSC55 0·29 (0·00–80·15) 65 12F (Israel) ·· 65 (100%) 0
GPSC168 0·22 (0·09–0·50) 5 15A (South Africa) ·· 5 (100%) 5 (100%)
GPSC25 0·21 (0·03–1·40) 12 15B/C (South Africa) ·· 0 0
GPSC6 0·16 (0·03–0·82) 8 ·· 9V→15B/C (USA)¶ 2 (25%) 2 (25%)
GPSC139 0·16 (0·00–8·87) 9 10B (Israel) ·· 0 0
GPSC132 0·12 (0·01–1·04) 5 15B/C (USA)¶ ·· 5 (100%) 5 (100%)
Serotypes with a significantly higher invasive disease potential (odds ratio for invasiveness >1, p value <0·05)18 were 8, 19A, and 12F. Serotypes with a significantly 
lower invasive disease potential (odds ratio for invasiveness <1, p value <0·05) were 15A, 15B/C, 23B, 21, and 35B. VT=vaccine serotype. IPD=invasive pneumococcal 
disease. PCV=pneumococcal conjugate vaccine. GPSC=Global Pneumococcal Sequence Cluster. *Calculated for Israel, South Africa, and the USA, where annual incidence 
of IPD was available; data are per 100 000 children. †Number of isolates from all six countries in the PCV13 period. ‡Increase in disease caused by non-VT GPSCs 
(ie, those expressing >50% non-vaccine serotypes in the pre-PCV13 period) in incidence for Israel, South Africa, and the USA, and in prevalence for Hong Kong, 
Malawi, and The Gambia. §Increase in non-VT component within VT-GPSCs (ie, those expressing ≥50% vaccine serotype in the pre-PCV period); data are presented as 
predominant serotype in the pre-PCV period → predominant serotype in the PCV13 period (country). ¶Significant increase was observed only between the 
PCV7 and PCV13 periods.
Table 3: GPSCs causing non-VT IPD in the PCV13 era 
Number of isolates (%) Adjusted p value by 
linear regression*
Pre-PCV period PCV13 period
Overall (n) 1577 814 ··
Penicillin 774 (49%) 277 (34%) <0·0001
Chloramphenicol 78 (5%) 39 (5%) 0·93
Erythromycin 377 (24%) 122 (15%) <0·0001
Cotrimoxazole 1118 (71%) 399 (49%) <0·0001
Tetracycline 446 (28%) 148 (18%) <0·0001
Multidrug resistance† 410 (26%) 125 (15%) <0·0001
Non-VT isolates only (n) 249 575 ··
Penicillin 52 (21%) 169 (29%) 0·0016
Chloramphenicol 14 (6%) 31 (5%) 0·33
Erythromycin 3 (1%) 65 (11%) 0·0031
Cotrimoxazole 120 (48%) 224 (39%) 0·021
Tetracycline 36 (14%) 80 (14%) 0·83
Multidrug resistance† 21 (8%) 59 (10%) 0·79
PCV=pneumococcal conjugate vaccine. PCV13=13-valent pneumococcal conjugate vaccine. VT=vaccine serotype. 
*A generalised linear regression to detect the significant correlation between PCV13 introduction and changes in 
antibiotic prevalence after accounting for the variations between countries. †Multidrug resistance was defined as 
isolates non-susceptible to three or more classes of antibiotics detected in this study.
Table 4: Changes in prevalence of antibiotic non-susceptibility between pre-PCV and PCV13 periods
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to chloram phenicol (31 [89%] of 35), tetracycline (32 [91%] 
of 35), and cotrimoxazole (35 [100%] of 35; appendix 1), 
although remained susceptible to penicillin (table 3).
In the PCV13 period, we observed differences 
in prevalence of antibiotic non-susceptibility between 
countries within a lineage (appendix 1). Compared with 
other countries, GPSC3 and GPSC5 isolates from the USA 
had a higher prevalence of resistance to erythromycin, 
mostly (13 [87%] of 15) mediated by mefA, whereas isolates 
from Israel belonging to GPSC3 had a higher prevalence 
of resistance to penicillin (appendix 1). For GPSC3, the 
prevalence of erythromycin resistance mediated by mefA 
in the USA was zero in the pre-PCV period, but increased 
to 46% (12 of 26) in the PCV7 period and to 67% (12 of 18) 
in the PCV13 period (pre-PCV vs PCV13 period, p=0·0287). 
By contrast, changes in cotrimoxazole resistance in 
that lineage were not significant (appendix 1). In Israel, 
prevalence of penicillin resistance in GPSC3 did not 
significantly change between pre-PCV (five [45%] of 11) 
and PCV7 (one [50%] of two, p=1·000) or PCV13 
(four [29%] of 14, p=0·4341) periods.
Discussion
Our analyses showed that globally spreading lineages 
expressing invasive serotypes had an important role 
in serotype replacement. The high-resolution and 
standardised population structure allowed us to 
understand the lineages that drove the increases in non-
vaccine-type invasive pneumococcal disease beyond 
serotypes at local and international levels.
We found that the same serotype could be associated 
with different major lineages in different countries 
(eg, serotype 12F was associated with GPSC55 in Israel but 
GPSC26 in The Gambia and South Africa). Such variations 
might be explained by differences in the initial bacterial 
population, host characteristics, or antibiotic selective 
pressures between countries. For example, although 
GPSC26 persisted in Israel without significant changes in 
incidence between pre-PCV and PCV13 periods, GPSC55, 
with 100% resistance to penicillin, significantly increased 
in Israel in that time, which might be due to the common 
use of β-lactam antibiotics for treating pneumococcal 
disease in the country.33 By contrast, GPSC26, with 
cotrimoxazole resistance but susceptibility to penicillin, 
was the predominant lineage, accounting for most of the 
serotype 12F isolates, in The Gambia and South Africa, 
where cotrimoxazole is widely used to prevent bacterial 
infection in people with HIV.34,35 In South Africa, we 
observed that a serotype 15B/C lineage (GPSC25) replaced 
another serotype 15B/C lineage (GPSC48) during the 
introduction of PCVs; an event known as clonal 
replacement. Clonal replacement was also reported among 
serotype 19A pneumococci in the USA following the 
introduction of PCV7, in which sequence type (ST) 
320 outcompeted ST199.36 Further investigation into the 
genomic differences between the two STs might help 
explain these observations.
We found that major lineages could be associated with 
different serotypes in different countries, such as lineages 
GPSC3 (eg, serotype 8 in South Africa and 33F in the 
USA), GPSC5, and GPSC11. Before the introduction of 
PCVs, high serotype diversity was already observed in 
these three lineages, with the highest in GPSC11 
(Simpson’s diversity index 0·84, ranked the first of 
621 lineages in our previous study), followed by GPSC5 
(0·75, ranked second) and GPSC3 (0·72, ranked fifth).18 
GPSC3 and GPSC5 were reported to be the cause of 
invasive pneumococcal disease internationally before the 
introduction of PCVs and classified by the Pneumococcal 
Molecular Epidemiology Network as PMEN33 and 
PMEN26, respectively.37 Such established international 
lineages are important to consider when attempting to 
identify a global solution for the control of pneumococcal 
disease.
Non-vaccine-type GPSCs, rather than the vaccine-type 
GPSCs with a non-vaccine-type component, accounted for 
the largest proportion (>59%) of invasive pneumo coccal 
disease caused by non-vaccine serotypes after the 
introduction of PCV13. However, we observed that only 
eight non-vaccine-type lineages increased significantly in 
this dataset following the introduction of PCV13. This 
finding suggests that non-vaccine-type lineages that 
persisted in the population without increasing in 
prevalence also had an important part in causing disease 
when invasive pneumococcal disease caused by vaccine 
serotypes decreased. For example, a lineage expressing 
serotype 22F, GPSC19, ranked second in contribution to 
non-vaccine-type invasive pneumococcal disease in the 
PCV13 period but was not detected to have increased in 
either Israel or the USA. Of note, such non-vaccine-type 
lineages (GPSC19, GPSC38, GPSC48, GPSC9, GPSC7, 
and GPSC36; appendix 1) were found in several countries 
and expressed serotypes that were observed to be major 
non-vaccine serotypes causing invasive pneumococcal 
disease in multiple countries after PCV13 introduction.3,6,38,39 
The application of GPSCs to isolates from additional 
countries could allow better understanding of these non-
vaccine serotypes importance to disease replacement.
Among the ten most prevalent lineages causing non-
vaccine-type invasive pneumococcal disease in the PCV13 
period, two (GPSC3 and GPSC26) expressed invasive 
serotypes 8, 12F, and 33F. Increases in serotype 12F 
resulting in disease replacement were reported in 
England and Wales,6 France,9,40 and Germany,39 although 
the genotypes of those isolates were not reported. 
Globally, serotype 12F isolates mainly belong to clonal 
complex (CC) 989 (GPSC26),41,42 but also to ST218 
(GPSC32) in North America43,44 and CC3524 (GPSC55), a 
regional lineage, in Israel. Increase in serotype 8 was also 
observed among children less than 5 years of age in 
England and Wales in 2016-17.6 A 10-year invasive 
pneumococcal disease study45 done in Oxfordshire in 
1996–2005 showed that all serotype 8 disease isolates 
were ST53 (GPSC3); therefore, GPSC3 might also be 
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involved in disease replacement in England and Wales. In 
the post-PCV13 era, invasive serotype 33F pneumococci 
were reported to be one of the major non-vaccine types 
causing childhood invasive pneumococcal disease in 
North America;46 they were predominantly CC100 
(GPSC3) in Canada and the USA and associated with 
erythromycin resistance.47,48 Invasive disease potential for 
serotype 22F was inconsistent across the literature.18,49,50 
The genetic background for serotype 22F isolates was not 
diverse and mainly associated with CC433 (GPSC19). The 
other ten most prevalent lineages express non-vaccine 
serotypes that are not significantly associated with disease 
(serotypes 6C, 10A, 15A, 15B/C, 21, 22F, 23A, 23B, 35B, 
and 38; appendix 1).18 The invasive disease potential of 
serotypes is not the only determinant of disease 
replacement; serotypes with low invasive disease potential 
can still cause disease among individuals with comorbid 
conditions. Furthermore, given that nasopharyngeal 
carriage of pneumococcus could be a risk for proceeding 
into invasive disease, frequent colonisers, such as 
serotypes 15B/C and 35B, might be sufficiently prevalent 
in carriage for expansion to result in significant disease 
replacement.51,52
Despite the overall reductions in prevalence of anti- 
biotic resistance in pneumococci after the use of PCVs, 
signi ficant increases in penicillin and erythromycin 
resistance among non-vaccine-type isolates were observed 
in the PCV13 period. Penicillin is the first-line antibiotic 
in the treatment of pneumococcal disease. The increasing 
empirical use of macrolides for pneumonia has been 
observed in high-income countries, such as the USA, 
due to their broader spectrum activity against aty- 
pical pneumonia caused by Mycoplasma pneumoniae, 
Chlamydia pneumoniae, and Bordetella pertussis.53–55 The 
increase in penicillin and erythromycin resistance could 
be due to acquisition of resistance determinants (eg, mefA 
in GPSC3 in the USA), the expansion of extant non-
vaccine serotypes within a well established resistant 
lineage (eg, penicillin-resistant lineage GPSC5 replacing 
its major serotype composition from serotype 23F to 35B/D 
in South Africa), or simply a clonal expansion of a 
non-vaccine-type lineage with antimicrobial resistance 
(eg, penicillin and macrolide resistant GPSC59 in the 
USA). Additionally, this study revealed differences in 
resistance prevalence within a single lineage between 
countries, indicating that some surviving lineages could 
acquire antibiotic resistance determinants adaptive to the 
local antibiotic selective pressure.
A limitation of this study is the relatively short length 
of sampling time after PCV13 introduction, as indicated 
by the presence of residual PCV13 serotypes in the top 
five serotypes in some countries, especially in the USA. 
This limitation also hinders our ability to account for 
secular trends. Given this context, the described changes 
are early indicators of restructuring of the population 
towards its new equilibrium. Subtler changes, taking 
longer to manifest, would not have been detected, but 
the effects of local population structure on serotype 
replacement is clear. Despite small numbers of samples 
per year throughout the pre-PCV period in Hong Kong 
and The Gambia, collections were representative of the 
baseline population in each country (PMC15308357 and 
PMC16827713). The small number of samples from 
Malawi after introduction of PCV13 was the result of the 
low incidence of pneumooccal disease in that period, 
rather than a problem of low representation. Increasing 
surveillance intensity was observed in South Africa 
during the first 3 years of the pre-PCV period; therefore, 
we might have underestimated the actual reductions in 
vaccine sero types and overestimated the actual increase 
in non-vaccine serotypes.2 However, the surveillance 
intensity in the last 2 years of the pre-PCV period were 
similar to the rest of the study periods.
In conclusion, globally spreading lineages expressing 
invasive serotypes have an important role in serotype 
replacement, and emerging non-vaccine serotypes 
associated with different pneumococcal lineages in 
different countries might be explained by local antibiotic 
selective pressures. Continued genomic surveillance of the 
dynamics of pneumococcal populations with increased 
geographical representation in the post-vaccine period will 
generate further knowledge for optimising future vaccine 
design.
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